143 related articles for article (PubMed ID: 28710189)
1. Use of cabergoline for the management of persistent Cushing's disease in pregnancy.
Sek KS; Deepak DS; Lee KO
BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710189
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline treatment for recurrent Cushing's disease during pregnancy.
Nakhleh A; Saiegh L; Reut M; Ahmad MS; Pearl IW; Shechner C
Hormones (Athens); 2016 Jul; 15(3):453-458. PubMed ID: 27394707
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline therapy for Cushing disease throughout pregnancy.
Woo I; Ehsanipoor RM
Obstet Gynecol; 2013 Aug; 122(2 Pt 2):485-487. PubMed ID: 23884269
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy for Cushing's disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?
Barbot M; Albiger N; Ceccato F; Zilio M; Frigo AC; Denaro L; Mantero F; Scaroni C
Pituitary; 2014 Apr; 17(2):109-17. PubMed ID: 23468128
[TBL] [Abstract][Full Text] [Related]
5. A successful case of Cushing's disease pregnancy treated with ketoconazole.
Costenaro F; Rodrigues TC; de Lima PB; Ruszczyk J; Rollin G; Czepielewski MA
Gynecol Endocrinol; 2015 Mar; 31(3):176-8. PubMed ID: 25561184
[TBL] [Abstract][Full Text] [Related]
6. Remission with cabergoline in adolescent boys with Cushing's disease.
Güven A; Baltacıoğlu F; Dursun F; Cebeci AN; Kırmızıbekmez H
J Clin Res Pediatr Endocrinol; 2013 Sep; 5(3):194-8. PubMed ID: 24072089
[TBL] [Abstract][Full Text] [Related]
7. Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report.
Manavela MP; Danilowicz K; Bruno OD
Pituitary; 2012 Dec; 15 Suppl 1():33-6. PubMed ID: 22038028
[TBL] [Abstract][Full Text] [Related]
8. [Use of cabergoline in persisting Cushing's disease].
Illouz F; Dubois-Ginouves S; Laboureau S; Rohmer V; Rodien P
Ann Endocrinol (Paris); 2006 Sep; 67(4):353-6. PubMed ID: 17072242
[TBL] [Abstract][Full Text] [Related]
9. How to diagnose and manage Cushing's disease during pregnancy, when hypercortisolism is mild?
Ragonese M; Cotta OR; Ferraù F; Trimarchi F; Cannavò S
Gynecol Endocrinol; 2012 Aug; 28(8):637-9. PubMed ID: 22309603
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline for Cushing's disease: a large retrospective multicenter study.
Ferriere A; Cortet C; Chanson P; Delemer B; Caron P; Chabre O; Reznik Y; Bertherat J; Rohmer V; Briet C; Raingeard I; Castinetti F; Beckers A; Vroonen L; Maiter D; Cephise-Velayoudom FL; Nunes ML; Haissaguerre M; Tabarin A
Eur J Endocrinol; 2017 Mar; 176(3):305-314. PubMed ID: 28007845
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline may act as a radioprotective agent in Cushing's disease.
Thakkar K; Lila A; Sarathi V; Ramteke-Jadhav S; Goroshi M; Memon SS; Krishnatry R; Gupta T; Jalali R; Goel A; Shah A; Sankhe S; Patil V; Bandgar T; Shah NS
Clin Endocrinol (Oxf); 2020 Jan; 92(1):55-62. PubMed ID: 31698511
[TBL] [Abstract][Full Text] [Related]
12. Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.
Burman P; Edén-Engström B; Ekman B; Karlsson FA; Schwarcz E; Wahlberg J
Eur J Endocrinol; 2016 Jan; 174(1):17-24. PubMed ID: 26582653
[TBL] [Abstract][Full Text] [Related]
13. The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy.
van der Pas R; de Bruin C; Leebeek FW; de Maat MP; Rijken DC; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Lamberts SW; Hofland LJ; Feelders RA
J Clin Endocrinol Metab; 2012 Apr; 97(4):1303-10. PubMed ID: 22278425
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease.
Vilar L; Naves LA; Azevedo MF; Arruda MJ; Arahata CM; Moura E Silva L; Agra R; Pontes L; Montenegro L; Albuquerque JL; Canadas V
Pituitary; 2010 Jun; 13(2):123-9. PubMed ID: 19943118
[TBL] [Abstract][Full Text] [Related]
15. Cortisol diurnal rhythm and quality of life after successful medical treatment of Cushing's disease.
van der Pas R; de Bruin C; Pereira AM; Romijn JA; Netea-Maier RT; Hermus AR; Zelissen PM; de Jong FH; van der Lely AJ; de Herder WW; Webb SM; Lamberts SW; Hofland LJ; Feelders RA
Pituitary; 2013 Dec; 16(4):536-44. PubMed ID: 23225121
[TBL] [Abstract][Full Text] [Related]
16. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.
Berwaerts J; Verhelst J; Mahler C; Abs R
Gynecol Endocrinol; 1999 Jun; 13(3):175-82. PubMed ID: 10451809
[TBL] [Abstract][Full Text] [Related]
17. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
18. Successful outcome of pregnancy in a patient with Cushing's disease under treatment with ketoconazole during the first trimester of gestation.
Boronat M; Marrero D; López-Plasencia Y; Barber M; Schamann Y; Nóvoa FJ
Gynecol Endocrinol; 2011 Sep; 27(9):675-7. PubMed ID: 20923280
[TBL] [Abstract][Full Text] [Related]
19. The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.
Pivonello R; De Martino MC; Cappabianca P; De Leo M; Faggiano A; Lombardi G; Hofland LJ; Lamberts SW; Colao A
J Clin Endocrinol Metab; 2009 Jan; 94(1):223-30. PubMed ID: 18957500
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline monotherapy in the long-term treatment of Cushing's disease.
Godbout A; Manavela M; Danilowicz K; Beauregard H; Bruno OD; Lacroix A
Eur J Endocrinol; 2010 Nov; 163(5):709-16. PubMed ID: 20702648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
